LabCorp to Announce Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 16, 2019-- LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb. 7, 2019 , and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

LabCorp and Texas Association of Community Health Centers Extend Agreement for LabCorp to Be Exclusive Laboratory for Community Health Centers Across Texas

LabCorp Will Provide Enhanced Laboratory Services, With an Emphasis on Chronic Diseases, for Clinics Serving More Than One Million Patients Annually BURLINGTON, N.C. & AUSTIN, Texas --(BUSINESS WIRE)--Jan. 15, 2019-- LabCorp® (NYSE: LH) a leading global life sciences company, and the Texas

Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LILLE, France & CAMBRIDGE, Mass. & BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences

LabCorp is Scheduled to Present at the 37th Annual J.P. Morgan Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 2, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 37th Annual J.P. Morgan Healthcare Conference . LabCorp’s presentation is scheduled for Tuesday, January 8, 2019 at 1:30 p.m. (PT) , followed by a question and answer session at 2:00

Covance Xcellerate® Wins Best Technological Development in Clinical Trials (Clinical Sponsor-Focused) at 14th Annual Scrip Awards

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 7, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development (Covance) business was awarded Best Technological Development in Clinical Trials (Clinical Sponsor-Focused) at the 14th Annual Scrip